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Objective: To evaluate the efficacy and safety of adjuvant IFN therapy for viral hepatitis-related hepatocellular
carcinoma (HCC) after treatment with surgical resection or transarterial chemoembolization (TACE).
Methods: Controlled trials of adjuvant treatment with IFN for patients with HCC published between 2000 and 2012
were searched electronically in MEDLINE, PubMed, Cochrane Library, and EMBASE databases. According to the
heterogeneity of the studies, two different models - the fixed-effect model and the random-effect model - were
applied to analyze the results.
Results: Ten trials were screened according to inclusion and exclusion standards. Eight randomized, controlled trials
and two non-randomized, controlled trials were included. These ten trials with a total of 1,029 subjects were
eventually involved in the meta-analysis; 528 HCC patients were treated with adjuvant treatment with IFN and 501
patients with placebo. Compared to the control group, the recurrence rates of HCC in IFN group were significantly
lower (odds ratio (OR) = 0.66; 95% confidence interval (CI) = 0.50 to 0.86; P = 0.02), especially after TACE treatment
according to subgroup analysis (OR = 0.73; 95% CI = 0.52 to 1.01; P = 0.06 for surgical resection; and OR = 0.54;
95% CI = 0.33 to 0.86, P = 0.01 for TACE). The death rates in the IFN group also significantly decreased according to
not only total events analysis (OR = 0.42; 95% CI = 0.32 to 0.56; P < 0.00001) but also subgroup analysis (OR = 0.51;
95% CI = 0.36 to 0.72; P = 0.0002 for surgical resection; and OR = 0.33; 95% CI = 0.21 to 0.50; P < 0.00001 for TACE).
Conclusions: Adjuvant IFN therapy may significantly reduce the recurrence rates of patients with viral hepatitis-
related HCC and improve the survival of patients after surgical resection or TACE. The ideal dose mostly selected is
3 MIU/ml, three times per week, which can make patients tolerate the adverse reactions of IFN better and maintain
effective concentrations for a long time.
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Introduction
Primary liver cancer, which consists predominantly of he-
patocellular carcinoma (HCC), is the fifth most common
cancer worldwide and the third most common cause of
cancer mortality [1]. Due to the high degree of malignancy
and the difficulty of diagnosis in the early stage, the lesions
of most patients have already metastasised when they first
see a doctor [2]. However, only approximately 10 to 30%* Correspondence: jiangshaojie130916@163.com
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reproduction in any medium, provided the orof patients may have the opportunity to receive radical
therapies such as liver transplantation [3], but liver trans-
plantation is only suitable for a small group of patients be-
cause of its high cost and strict selection criteria.
Therefore, most patients receive surgical resection or
transarterial chemoembolization (TACE) treatment [4].
Unfortunately, the recurrence rate of HCC 3 years after
pure surgical resection or TACE is more than 50%, which
is also the main cause of death after treatment [5]. As we
know, most HCC patients carry the hepatitis B virus
(HBV) and the hepatitis C virus (HCV). Since IFN can in-
hibit the replication of HBV and HCV and also kill the
cancer cells, several researchers believe IFN may reducetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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But the conclusion is not consistent [6-8]. This paper
raised clinical data through a Cochrane system evaluation,
and used fixed/random effect models to perform a meta-
analysis in order to study the therapeutic effects of
radiofrequency ablation and hepatic resection in the treat-





We reviewed all studies reporting the results of trials on
the therapeutic effects of adjuvant treatment with IFN
for patients with hepatocellular carcinoma (HCC). Com-
puterized literature searches of MEDLINE, PubMed,
Cochrane Library, and EMBASE databases, from 2000 to
2012, were undertaken. Search terms used were 'hepato-
cellular carcinoma', 'liver cancer', 'liver neoplasm', 'inter-
feron', and 'IFN'. These terms were used in different
combinations with each other. In addition, we reviewed
the reference lists of the original articles and reviews on
the topic to identify other possible eligible trials.
Study selection
The inclusion criteria for this meta-analysis were as fol-
lows: (1) all cases were diagnosed as HCC through path-
ology tests and combined with viral hepatitis (HBV/
HCV); (2) both the IFN group and control group were
treated with surgical resection or TACE; (3) adjuvant
treatment with IFN lasted more than 3 months after the
first treatment (surgical resection or TACE); (4) follow-
up time was greater than 1 year, and the control group
was treated with placebo; (5) the study subjects are all
controlled clinical trial cases; (6) sample size greater
than 20 cases.
The exclusion criteria for this meta-analysis were as
follows: (1) metastatic hepatic carcinoma or recurrent
liver cancers that have already been treated; (2) full text
of the trial was not available; (3) when multiple publica-
tions from a single institution/author appeared to in-
clude duplication of patients, the study with smaller
patient group was excluded; (4) follow-up time less than
1 year; (5) sample size ≤20 cases.
Data extraction
All literature searches were independently reviewed by
two authors (CD and ML) to identify relevant trials that
met the inclusion criteria and were checked by an inde-
pendent reviewer. Disparities were resolved by discus-
sion and mailed to the authors for explanation.
Included studies were reviewed based on the random
fashion method, blind method and lost to follow-ups of
the allocation plan. The grades to the creditability of thestudies were divided into three grades according to
Cochrane system evaluation handbook [9]: Grade A
cases met all evaluated standards and had correct meth-
odology, which gave a low risk of bias; Grade B cases
did not describe one or several standards, which gave a
moderate risk of bias; Grade C cases had one or several
standards incorrect, which gave a high risk of bias. The
methodology quality evaluations gave two studies as
Grade A and eight studies as Grade B. Study quality was
independently assessed by two reviewers (Table 1).Data analysis
Statistical analyses were performed using Review Manager
Software (RevMan 5.2; Cochrane Collaboration, Oxford,
UK). Continuous descriptive data of the IFN group and
the control group were reported as the mean ± standard
deviation and dichotomous data were recorded as the case
number (n).
The Mantel-Haenszel Q-statistic was used to assess
heterogeneity among the studies and the I2 statistic was
computed to examine the proportion of total variation
in the study estimate due to heterogeneity. We consid-
ered P > 0.10 or P ≤ 0.10, I2 ≤ 50% to indicate no signifi-
cant heterogeneity between the trials and selected a
fixed-effect model to perform analysis. Furthermore, we
considered P ≤ 0.10, I2 > 50% to indicate significant het-
erogeneity and used a random-effect model to perform
analysis. The integration results regarded P < 0.05 as the
standard for statistical significance.
Extensive effort was made to remove all duplicated
data and to include all studies published to date. Publi-
cation bias in outcomes was assessed and treated using
standard methodology. Funnel plots were used to visu-
ally inspect the relationship between sample size and
treatment effects for the two groups.Results
Search results
A total of 403 relevant articles were identified in a com-
bined search of MEDLINE, PubMed, Cochrane Library
and EMBASE databases, from 2000 to 2012, and by a
manual approach (search of studies cited in previous re-
views and of reference lists from the identified articles);
368 articles were excluded because they were not rele-
vant for the purpose of this meta-analysis through scan-
ning the title/abstract. Full-length articles could not be
retrieved for 14 of the 35 accepted articles for various
reasons. Of the 21 full articles retrieved, 11 articles were
excluded (see Figure 1 for the reasons). Eventually, 10
articles with a total of 1,029 subjects were included in
the systematic review, including eight randomized, con-
trolled trials and two non-randomized, controlled trials
(Figure 1).
Table 1 Assessment quality of included studies
Study Trial type Randomization allocation concealment Blinding Lost of follow up ITT Grade
Kubo S (2002) [9] RCT Adequate Unclear Adequate Yes Yes B
Shiratori Y (2003) [10] RCT Adequate Adequate Adequate Yes Yes A
Lin SM (2004) [11] RCT Unclear Unclear Unclear Yes Yes B
Piao CY (2005) [12] RCT Adequate Unclear Adequate Yes Yes B
Mazzaferro V (2006) [13] RCT Adequate Unclear Unclear Yes Yes B
Sun HC (2006) [14] RCT Adequate Adequate Adequate Yes Yes A
Lo CM (2007) [15] RCT Adequate Adequate Unclear Yes Yes B
Li M (2009) [16] RCT Adequate Unclear Unclear Yes Yes B
Li N (2010) [17] NRCT Adequate Adequate Unclear Yes Yes B
Ishikawa (2012) [18] NRCT Adequate Unclear Unclear Yes Yes B
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the meta-analysis: 528 HCC patients were treated with
adjuvant treatment with IFN and 501 patients with pla-
cebo. The longest follow-up time was 85.2 months and
the shortest follow-up time was 24.0 months. The largest
sample size was 236 and the smallest size was 30. The
characteristics of the 10 studies included in the meta-
analysis arre listed in Table 2 and the applications of ad-
juvant treatment with IFN in the IFN group are listed in
Table 3.
Meta-analysis
We primarily compared recurrence rates and death rates
for HCC between radiofrequency ablation (RFA) andFigure 1 Process of study selection. The excluded 11 articles
include eight articles without controlled trials, one article’s patients
follow-up less than one year ,one article’s sample size <=20 cases
and two articles from a single author appeared to include
duplication of patients, only the study with the largest patient group
was included and the other one was excluded.hepatic resection (HR) in the treatment of small HCC.
In order to further detect if there are any difference in
recurrence rates and death rates based on the different
treatment types, we performed subgroup analysis based
on the treatment type (surgical resection/TACE). The re-
sults of meta-analysis for each indicator are listed below.
Recurrence rates for hepatocellular carcinoma
Nine studies including 975 cases [9-17] compared the
IFN group and the control group with regard to the
recurrence rates of HCC. Taking the odds ratio (OR)
as an indicator of the effect of measures, we
performed a χ2 test to examine the heterogeneity; the
result was P = 0.67 (>0.10), I2 = 0% (<50%), which in-
dicated that there was no heterogeneity between the
two groups. Therefore, we used a fixed-effect model to
perform a meta-analysis. The results (OR = 0.66; 95%
confidence interval (CI) = 0.50 to 0.86, P = 0.02) indi-
cated that adjuvant treatment with IFN might signifi-
cantly decrease the recurrence rates of HCC after
initial treatment.
In order to further reinforce the conclusion above, we
performed subgroup analysis based on the treatment
type (surgical resection/TACE). We performed a χ2 test
to examine the heterogeneity; the results were P = 0.60
(>0.10), I2 = 0% (<50%) and P = 0.57 (>0.10), I2 = 0%
(<50%), respectively, which indicated that there was no
heterogeneity. Therefore, we used a fixed-effect model.
The results (OR = 0.73; 95% CI = 0.52 to 1.01; P = 0.06
for surgical resection; and OR = 0.54; 95% CI = 0.33 to
0.86; P = 0.01 for TACE) indicated that there was a sig-
nificant difference between the IFN group after TACE
treatment and the control group for recurrence of HCC,
and there was no difference between the IFN group after
surgical resection and the control group (Figure 2).
Death rates for hepatocellular carcinoma
Nine studies including 949 cases [9-11,13-18] compared
the IFN group and the control group with regard to the
Table 2 Characteristics of the studies included in the meta-analysis















Kubo S (2002) Interferon 15 61.9 100.0 2.5 0 46.7 73.3/26.7 HCV Surgical resection
Placebo 15 60.0 100.0 2.6 0 52.2 80.0/20.0
Shiratori Y (2003) Interferon 49 61.0 71.4 2.2 34.7 100.0 – HCV Surgical resection
Placebo 25 63.0 68.0 2.3 36.0 100.0 –
Lin SM (2004) Interferon 20 61.5 80.0 2.2 15.0 90.0 85.0/15.0 HBV/ HCV TACE
Placebo 10 59.0 70.0 2.5 20.0 100.0 90.0/10.0
Piao CY (2005) Interferon 30 59 76.7 2.3 23.3 13.0 60.0/36.7 HBV/ HCV Ablation/TACE/
surgical resection
Placebo 40 58 72.5 2.5 17.5 23.0 55.0/42.5
Mazzaferro V (2006) Interferon 76 65.0 80.3 3.4 22.4 94.0 92.1/7.9 HCV Surgical resection
Placebo 74 67.0 68.9 3.2 25.7 88.0 94.6/5.4
Sun HC (2006) Interferon 118 52.2 89.8 4.3 13.6 83.1 – HBV Surgical resection
Placebo 118 50.4 86.4 4.9 12.7 88.1 –
Lo CM (2007) Interferon 40 49.0 77.5 5.5 17.5 47.5 – HBV/ HCV Surgical resection
Placebo 40 54.0 85.0 5.7 27.5 47.5 –
Li M (2009) Interferon 108 50.3 71.3 4.9 54.6 100.0 90.7/9.3 HBV TACE
Placebo 108 49.2 68.5 4.8 54.6 100.0 91.7/8.3
Li N (2010) Interferon 43 53.2 72.5 3.2 37.2 88.0 85.0/15.0 HBV TACE
Placebo 36 51.2 71.3 3.4 37.2 88.0 85.0/15.0
Ishikawa (2012) Interferon 29 59.0 83.2 2.3 13.5 100.0 – HCV TACE
Placebo 25 58.7 81.2 2.5 17.4 100.0 –
Abbreviation: TACE trans-catheter arterial chemoembolization.
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effect of measures, we performed a χ2 test to examine
the heterogeneity; the result was P = 0.54 (>0.10), I2 =
0% (<50%), which indicated that there was no heterogen-
eity between the two groups. Therefore, we used a fixed-
effect model to perform a meta-analysis. The results
(OR = 0.42; 95% CI = 0.32 to 0.56, P < 0.00001)
indicated that adjuvant treatment with IFN mightTable 3 Applications of adjuvant treatment with interferon in
Study Interven
Ikeda K (2000) 10 patients received natural IFN-β 6×
Kubo S (2000) 15 patients received 6×106 IFN-α intra
then three times weekly for 14 weeks, an
Shiratori Y (2003) 49 patients received 6×106 IFN-α intramusc
Lin SM (2004) 20 patients received 3×106 IFN-α 2b intramusc
Piao CY (2005) 30 patients orally received 100 mg of lam
Mazzaferro V (2006) 76 patients received 3×106 IFN-α 2b t
Sun HC (2006) 118 patients received 3×106 IFN-α intramu
then 5×106 three times w
Lo CM (2007) 40 patients received 10×106/m2 IFN-α 2b subcu
Li M (2009) 108 patients received IFN-α 2b 3×106 three times
Li N (2010) 43 patients received lamivudine wit
Ishikawa (2012) 29 patients received PEG-IFN α-2b/ribasignificantly decrease the death rates of HCC after initial
treatment.
In order to further reinforce the conclusion above, we
performed subgroup analysis based on the treatment
type (surgical resection/TACE). We performed a χ2 test
to examine the heterogeneity; the results were P = 0.91
(>0.10), I2 = 0% (<50%) and P = 0.29 (>0.10), I2 = 19%
(<50%), respectively, which indicated that there was noIFN group
tion Follow-up (months)
106 twice a week for 36 months 25.0
muscularly every day for 2 weeks,
d finally twice weekly for 88 weeks.
60.0
ularly three times weekly for 48 weeks. 85.2
ularly three times weekly for 24 months. 27.0
ivudine daily after HCC treatment. 24.0
hree times weekly for 48 weeks. 45.0
scularly twice a week for 2 weeks and
eekly for 18 months.
36.5
taneously three times weekly for 16 weeks. 30.0
weekly by intramuscular injection one week. 24.8
h or without adefovir dipivoxil. 24.0











Heterogeneity: Chi² = 3.66, df = 5 (P = 0.60); I² = 0%







Heterogeneity: Chi² = 1.12, df = 2 (P = 0.57); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)
Total (95% CI)
Total events
Heterogeneity: Chi² = 5.83, df = 8 (P = 0.67); I² = 0%
Test for overall effect: Z = 3.04 (P = 0.002)
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0.05 0.2 1 5 20
IFN Placebo
Figure 2 The comparison between IFN group and control group in the recurrence rates of HCC. Abbreviation: IFN- interferon; TACE-
transarterial chemoembolization. Summary ORs are shown as diamonds, with the middle corresponding to the point estimate and the width
representing the 95% CI.
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The results (OR = 0.51; 95% CI = 0.36 to 0.72; P =
0.0002 for surgical resection; and OR = 0.33; 95% CI =
0.21 to 0.50; P < 0.00001 for TACE) indicated that there
was a significant difference between the IFN group and
the control group whether after surgical resection or
TACE treatment in the death rates of HCC (Figure 3).
Sensitivity analysis and publication bias
We used fixed/random-effect models to test each indica-
tor and the results were correlated with each other. We
made a funnel plot for each comparison (Figure 4), in-
cluding the subgroup comparisons. The characters of
both plots were basically inverted funnel-shaped, with
bilateral symmetry, which indicated that there was no
publication bias and the conclusions were reliable.
Discussion
This meta-analysis evaluates the efficacy and safety of
adjuvant IFN therapy for viral hepatitis-related HCC
after treatment by surgical resection or TACE. All cases
were combined with viral hepatitis (HBV/HCV). The re-
sults of the meta-analysis showed that there was a sig-
nificant difference between the IFN group and the
control group both in the recurrence rates and death
rates of HCC. In our clinical work, the main treatment
method for HCC is surgery and TACE [19]. In order to
exclude bias caused by treatment methods, we selectedHCC treated by surgery and TACE rather than other
curative treatments. We performed subanalysis between
surgical resection and TACE to ascertain any difference
between these two methods.
Only two included studies reported the adverse events
of adjuvant IFN therapy [11,15]. The major adverse
events were high fever, tiredness, a decrease in white
cells and platelets, hepatotoxicity and hyperthyroidism,
and so forth. The adverse events of IFN depend on the
dose. Randomized, controlled trials reported by Lo and
colleagues [15] were divided into a low-dose IFN group,
a high-dose IFN group, and a control group. All the
high-dose group (30 MIU/ml, three times per week) pa-
tients withdrew because of adverse events. The study by
Sakaguchi and colleagues [20] also showed that long-
term low-dose adjuvant IFN therapy could improve
patient tolerance, which may improve the prognosis of
treatment.
IFN has a variety of biological functions, such as anti-
virus, resistance to cell proliferation, anti-angiogenesis
and immune adjustment, and so forth, and has been
widely applied in many kinds of diseases [21,22]. Experi-
ments in vitro [23] showed that IFN-α could restrain the
proliferation of human umbilical vein endothelial cells
and its inhibition function was enhanced as the dose
and action time were extended. Experiments in vivo [24]
showed that the tumor diameter reduced significantly
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Heterogeneity: Chi² = 3.72, df = 3 (P = 0.29); I² = 19%
Test for overall effect: Z = 5.04 (P < 0.00001)
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IFN Placebo Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
IFN Placebo
Figure 3 The comparison between IFN and control group in the death rates of HCC. Abbreviation: IFN- interferon; TACE- transarterial
chemoembolization. Summary ORs are shown as diamonds, with the middle corresponding to the point estimate and the width representing the
95% CI.
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We can speculate that IFN-α realizes its anti-tumor ef-
fects by inhibiting tumor angiogenesis and resisting cell
proliferation. The biological characteristics above may
explain the benefit of adjuvant IFN therapy on HCC
patients.
Many researchers have found that the efficacy of IFN on
inducing Hepatitis Be Antigen (HBeAg) seroconversion isFigure 4 Funnel plot for each comparisons. A. Recurrence rate of HCC;
square represented TACE treatment for HCC.far from satisfactory [25], but we should realize that IFN
acted mainly as an antiviral, immunomodulatory and
antiproliferative agent and not as an inhibitor of the inte-
gration of HBV DNA [26]. IFN therapy improves overall
survival through relieving active hepatitis, improving hep-
atic fibrosis and liver function [27] as well as decreasing
the severity of a recurrent tumor and thus be amenable to
secondary curative ablation or resection [28]. From theB. Death rates of HCC; black circle represented surgical resection; red
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vent recurrence in HBV-related HCC patients, it still
shows long-term beneficial effects in HBV-related HCC in
other ways.
This study has the following limitations: (1) although
most of the included studies are randomized, controlled
trials, the sample sizes are relatively small; (2) the basic
characteristics of included cases are not all the same,
and the effect factors to prognosis of HCC include clin-
ical stage, pathological type, treatment methods, the size
of tumor and the body’s immune ability, which may also
affect the results of meta-analysis; (3) the included stud-
ies report mostly on the recurrence rate and death rate;
there are less reports on overall survival and disease-free
survival of adjuvant IFN therapy to HCC.
Conclusion
In conclusion, the meta-analysis based on 10 included
studies indicates that adjuvant IFN therapy may signifi-
cantly reduce the recurrence rates of patients with viral
hepatitis-related HCC and improve the survival of patients
after the treatment of surgical resection or TACE. The
ideal dose mostly selected is 3 MIU/ml, three times per
week, which can make patients tolerate the adverse reac-
tions of IFN better and maintain an effective concentra-
tion for a long time because of IFN dose dependence.
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